Design strategies for protein kinase inhibitors

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 5, 2004, Pages 617-629

  Parang, Keykavous ^a   Sun, Gongqin ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Inhibitor design; Protein kinases; Selectivity; Serine threonine kinases; Tyrosine kinases

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; BEVACIZUMAB; CANERTINIB; CEP 1347; CETUXIMAB; DORAMAPIMOD; GELDANAMYCIN; HEAT SHOCK PROTEIN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PELITINIB; PROTEIN SH2; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDO[2,3 D]PYRIMIDINE; PYRIMIDINE DERIVATIVE; RADICICOL; RUBOXISTAURIN; SU 66683; TRASTUZUMAB; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COLORECTAL CANCER; DIABETIC NEUROPATHY; DRUG BINDING SITE; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME CONFORMATION; HUMAN; LIVER TOXICITY; METASTASIS; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SRC HOMOLOGY DOMAIN; TUMOR MODEL;

CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR;

EID: 4944239923     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Manning G, Whyte DB, Martinez R, Hunter R, Sudarsanam S: The protein kinase complement of the human genome. Science (2002) 298(5600):1912-1934.
2. Hunter T: Signaling - 2000 and beyond. Cell (2000) 100(1):113-127.
3. Uckun FM, Mao C: Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia. Current Pharm Des (2004) 10(10):1083-1091.
4. Levitzki A: Protein kinase inhibitors as a therapeutic modality. Acc Chem Res (2003) 36(6):462-469.
5. Jiang G, Zhang BB: PI3-kinase and its up- and down-stream modulators as potential targets for the treatment of type II diabetes. Front Biosci (2002) 7:903-907.
6. Frame S, Cohen P: GSK3 takes centre stage more than 20 years after its discovery. Biochem J (2001) 359(Pt 1):1-16.
7. Vlahos CJ, McDowell SA, Clerk A: Kinases as therapeutic targets for heart failure. Nat Rev Drug Disc (2003) 2(2):99-113.
8. Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM: Inhibitors of protein kinase signaling pathways: Emerging therapies for cardiovascular disease. Circulation (2004) 109(10):1196-1205.
9. Mucke HA: CEP-1347 (Cephalon). IDrugs (2003) 6(4):377-383.
10. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL: Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology (2000) 47(2-3):185-201.
11. Traxler P: Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opin Ther Targets (2003) 7(2):215-234.
12. Druker BJ: Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol (2003) 40(1):50-58.
13. Wakeling AE: Epidermal growth factor receptor tyrosine kinase inhibitors. Curr Opin Pharmacol (2002) 2(4):382-387.
14. Marx SO, Marks AR: Bench to bedside: The development of rapamycin and its application to stent restenosis. Circulation (2001) 104(8):852-855.
15. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 344(11):783-792.
16. Mitchell P: Erbitux diagnostic latest adjunct to cancer therapy. Nat Biotechnol (2004) 22(4):363-364.
17. Roskoski R Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun (2004) 319(1):1-11.
18. Ferrara N, Hillan KJ, Gerber H-P, Novotony W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Disc (2004) 3(5):391-400.
19. Hubbard SR, Till JH: Protein tyrosine kinase structure and function. Annu Rev Biochem (2000) 69:373-398.
20. Cohen P: Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Disc (2002) 1(4):309-315. An excellent review of protein kinase inhibitors in clinical trials.
21. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H et al: Protein kinases as targets for anticancer agents: From inhibitors to useful drugs. Pharmacol Ther (2002) 93(2-3):79-98.
22. Fischer PM: The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr Med Chem (2004) 11(12):1563-1583.
23. Fischer OM, Streit S, Hart S, Ullrich A: Beyond Herceptin and Gleevec. Curr Opin Chem Biol (2003) 7(4):490-495.
24. Al-Obeidi FA, Wu JJ, Lam KS: Protein tyrosine kinases: Structure, substrate specificity and drug discovery. Biopolymers (1998) 47(3):197-223.
25. Toledo LM, Lydon NB, Elbaum D: The structure-based design of ATP-site directed protein kinase inhibitors. Curr Med Chem (1999) 6(9):775-805.
26. Traxler P: Tyrosine kinase inhibitors in cancer treatment (Part II). Expert Opin Ther Patents (1998) 8(12):1599-1625.
27. Bridges AJ: Chemical inhibitors of protein kinases. Chem Rev (2001) 101(8):2541-2571.
28. Myers MR, He W, Hulme C: Inhibitors of tyrosine kinases involved in inflammation and autoimmune disease. Curr Pharm Des (1997) 3(5):473-502.
29. Dancey J, Sausville EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Disc (2003) 2(4):296-313.
30. Nam NH, Parang K: Current targets for anticancer drug discovery. Curr Drug Targets (2003) 4(2):159-179.
31. Sawyer T, Boyce B, Dalgarno D, Luliucci J: Src inhibitors: Genomics to therapeutics. Expert Opin Investig Drugs (2001) 10(7):1327-1344.
32. Orchard S: Kinases as targets: Prospects for chronic therapy. Curr Opin Drug Discovery Dev (2002) 5(5):713-717.
33. Garcia-Echeverria C, Traxler P, Evans DB: ATP site-directed competitive and irreversible inhibitors of protein kinases. Med Res Rev (2000) 20(1):28-57.
34. Hubbard SR: Protein tyrosine kinases: Autoregulation and small molecule inhibition. Curr Opin Struct Biol (2002) 12(6):735-741.
35. Scapin G: Structural biology in drug design: Selective protein kinase inhibitors. Drug Disc Today (2002) 7(11):601-611.
36. Laird AD, Cherrington JM: Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents. Expert Opin Investig Drugs (2003) 12(1):51-64.
37. Williams DH, Mitchell T: Latest developments in crystallography and structure-based design of protein kinase inhibitors as drug candidates. Curr Opin Pharmacol (2002) 2(5):567-573.
38. Taylor SS, Radzio-Andzelm E: Three protein kinase structures define a common motif. Structure (1994) 2(5):345-355.
39. Wu SY, McNae I, Kontopidis G, McClue SJ, McInnes C, Stewart KJ, Wang S, Zheleva DI, Marriage H, Lane DP, Taylor P et al: Discovery of a novel family of CDK inhibitors with the program LIDAEUS: Structural basis for ligand-induced disordering of the activation loop. Structure (Camb) (2003) 11(4):399-410.
40. Stout TJ, Foster PG, Matthews DJ: High-throughput structural biology in drug discovery: Protein kinases. Curr Pharm Des (2004) 10(10):1069-1082.
41. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC: Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell (1999) 3(5):629-638.
42. Sawyer TK: Src homology-2 domains: Structure, mechanisms and drug discovery. Biopolymers (1998) 47(3):243-261.
43. Sicheri F, Moarefi I, Kuriyan J: Crystal structure of the Src family tyrosine kinase Hck. Nature (1997) 385(6617):602-609.
44. Xu W, Harrison SC, Eck MJ: Three-dimensional structure of the tyrosine kinase c-Src. Nature (1997) 385(6617):595-602.
45. Sicheri F, Kuriyan J: Structures of Src-family tyrosine kinases. Curr Opin Struct Biol (1997) 7(6):777-785.
46. Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, King F, Roberts T, Ratnofsky S, Lechleider RJ, Neel BG et al: SH2 domains recognize specific phosphopeptide sequences. Cell (1993) 72(5):767-778.
47. gag-fps. Mol Cell Biol (1986) 6(12):4396-4408.
48. Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziana A, Kapeller R, Soltoff S: Oncogenes and signal transduction. Cell (1991) 64(2):281-302.
49. Bain J, McLauchlan H, Elliott M, Cohen P: The specificities of protein kinase inhibitors: An update. Biochem J (2003) 371(Pt 1):199-204.
50. Huang M, Wang Y, Cogut SB, Mitchell BS, Graves LM: Inhibition of nucleoside transport by protein kinase inhibitors. J Pharmcol Exp Ther (2003) 304(2):753-760.
51. Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X, Moss KG, Louie SG, Mendel DB, Cherrington JM: SU6668 inhibits Flk-1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J (2002) 16(7):681-690.
52. Bishop AC: A hot spot for protein kinase inhibitor selectivity. Chem Biol (2004) 11(5):587-591.
53. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification. Science (2001) 293(5531):876-880.
54. Noble ME, Endicott JA, Johnson LN: Protein kinase inhibitors: Insights into drug design from structure. Science (2004) 303(5665):1800-1805. A current comprehensive review of the design of protein kinase inhibitors based on the available wealth of structural information.
55. Blencke S, Zech B, Engkvist O, Greff Z, Orfi L, Keri G, Ullrich A, Daub H: Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol (2004) 11(5):691-701.
56. Blencke S, Ullrich A, Daub H: Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem (2003) 278(17):15435-15440.
57. Rossé G, Séquin U, Mett H, Furet P, Traxler P, Fretz H: Synthesis of modified tripeptides and tetrapeptides as potential bisubstrate inhibitors of the epidermal growth factor receptor protein tyrosine kinase. Helv Chim Acta (1997) 80:653-670.
58. Yuan CJ, Jakes S, Elliot S, Graves D: A rationale for the design of an inhibitor of tyrosine kinase. J Biol Chem (1990) 265(27):16205-16209.
59. 4]-angiotensin I as a potential suicide substrate for protein-tyrosine kinases. Int J Pept Protein Res (1990) 36(6):538-543.
60. Bohmer FD, Kaagyozov L, Uecker A, Serve H, Botzki A, Mahboobi S, Dove S: A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP-site inhibitor STI-571. J Biol Chem (2003) 278(7):5148-5155.
61. Huse M, Kuriyan J: The conformational plasticity of protein kinases. Cell (2002) 109(3):275-282.
62. Bogoyevitch MA, Boehm I, Oakley A, Ketterman AJ, Barr RK: Targeting the JNK MAPK cascade for inhibition: Basic science and therapeutic potential. Biochim Biophys Acta (2004) 1697(1-2):89-101.
63. Shen GX: Selective protein kinase C inhibitors and their applications. Curr Drug Targets Cardiovasc Haematol Disord (2003) 3(4):301-307.
64. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J (2000) 351(Pt 1):95-105.
65. Lawrence DS, Niu J: Protein kinase inhibitors: The tyrosine-specific protein kinases. Pharmacol Ther (1998) 77(2):81-114.
66. Topaly J, Zeller WJ, Fruehauf S: Synergistic activity of the new Abl-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on Bcr-Abl-positive chronic myelogenous leukemia cells. Leukemia (2001) 15(3):342-347.
67. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ: Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood (2000) 96(9):3195-3199.
68. Kim H, Sasaki T, Maeda K, Koya D, Kashiwagi A, Yasuda H: Protein kinase C selective inhibitor LY333531 attenuates diabetic hyperalgesia through ameliorating cGMP level of dorsal root ganglion neurons. Diabetes (2003) 52(8):2102-2109.
69. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 19(13):3267-3279.
70. Tiseo M, Loprevite M, Ardizzoni A: Epidermal growth factor receptor inhibitors: A new prospective in the treatment of lung cancer. Curr Med Chem Anticancer Agents (2004) 4(2):139-148.
71. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Totzke F et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res (2000) 60(8):2178-2189.
72. Breier G, Blum S, Peli J, Groot M, Wild C, Risau W, Reichmann E: Transforming growth factor-β and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. Int J Cancer (2002) 97(2):142-148.
73. Ferrara N: VEGF: An update on biological and therapeutic aspects. Curr Opin Biotechnol (2000) 11(6):617-624.
74. Ferrara N: Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res (2000) 55:15-35.
75. Mendel DB, Laird AD, Xin X, Louie SG, Christensen SG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9(1):327-337.
76. Smith JK, Mamoon NM, Duhe RJ: Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol Res (2004) 14(4-5):175-225.
77. Rubinfeld H, Seger R: The ERK cascade as a prototype of MAPK signaling pathways. Methods Mol Biol (2004) 250:1-28.
78. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res (2002) 62(15):4236-4243.
79. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 2(5):561-566.
80. Druker BJ, Lydon NB: Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 105(1):3-7.
81. Buchdunger E, Cioffi CL, Law N, Stiver D, Ohno-Jones S, Druker BJ, Lyndon NB: Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther (2000) 295(1):139-145.
82. Okuda K, Weisberg E, Gilliland DG, Griffin JD: Arg tyrosine kinase activity is inhibited by ST1571, Blood (2001) 97(8):2440-2448.
83. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J: Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science (2000) 289(5486):1938-1942.
84. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bommann W, Clarkson B, Superti-Furga G, Kuriyan J: Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 112(6):859-871.
85. Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornmann WG, Bertino JR, Kuriyan J et al: Characterization of potent inhibitors of the Bcr-Abl and the c-Kit receptor tyrosine kinases. Cancer Res (2002) 62(15):4244-4255.
86. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J: Inhibition of p38 MAP kinase utilizing a novel allosteric binding site. Nat Struct Biol (2002) 9(4):268-272.
87. Delaney AM, Printen JA, Chen H, Fauman EB, Dudley DT: Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mol Cell Biol (2002) 22(21):7593-7602.
88. Lam KS, Wu J, Lou Q: Identification and characterization of a novel synthetic peptide substrate specific for Src-family protein tyrosine kinases. Int J Pept Protein Res (1995) 45(6):587-592.
89. Niu J, Lawrence DS: Nonphosphorylatable tyrosine surrogates. Implications for protein kinase inhibitor design. J Biol Chem (1997) 272(3):1493-1499.
90. c-src. Arch Biochem Biophys (1998) 355(1):124-130.
91. c-Src. Biochemistry (2000) 39(17):5221-5228.
92. Ramdas L, Obeyesekere NU, Sun G, McMurray JS, Budde RJ: N-Myristoylation of a peptide substrate for Src converts it into an apparent slow-binding bisubstrate-type inhibitor. J Pept Res (1999) 53(5):569-577.
93. c-Src protein tyrosine kinase using pseudosubstrate-based inhibitor design approach. J Pept Res (2003) 62(6):260-268.
94. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, Wright A, Vanderbilt C, Cobb MH: MAP kinases. Chem Rev (2001) 101(8):2449-2476.
95. Tanoue T, Nishida E: Docking interactions in the mitogen-activated protein kinase cascades. Pharmacol Ther (2002) 93(2-3):193-202.
96. Chang CI, Xu BE, Akella R, Cobb MH, Goldsmith EJ: Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. Mol Cell (2002) 9(6):1241-1249.
97. Bardwell AJ, Flatauer LJ, Matsukuma K, Thorner J, Bardwell L: A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission. J Biol Chem (2001) 276(13):10374-10386.
98. Ho DT, Bardwell AJ, Abdollahi M, Bardwell L: A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates. J Biol Chem (2003) 278(35):32662-32672.
99. c-Src. Arch Biochem Biophys (1996) 326(1):73-78.
100. Ruzzene M, Songyang Z, Marin O, Donella-Deana A, Brunati AM, Guerra B, Agostinis P, Cantley LC, Pinna LA: Sequence specificity of C-terminal Src kinase (CSK) - a comparison with Src-related kinases c-Fgr and Lyn. Eur J Biochem (1997) 246(2):433-439.
101. Miller WT: Determinants of substrate recognition in nonreceptor tyrosine kinases. Acc Chem Res (2003) 36(6):393-400.
102. Wang D, Huang XY, Cole PA: Molecular determinants for CSK-catalyzed tyrosine phosphorylation of the Src tail. Biochemistry (2001) 40(7):2004-2010.
103. Feuillet V, Semichon M, Restouin A, Harriague J, Janzen J, Magee A, Collette Y, Bismuth G: The distinct capacity of Fyn and Lck to phosphorylate Sam68 in T cells is essentially governed by SH3/SH2-catalytic domain linker interactions. Oncogene (2002) 21(47):7205-7213.
104. Schreiner SJ, Schiavone AP, Smithgall TE: Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem (2002) 277(47):45680-45687.
105. Pellicena P, Stowell KR, Miller WT: Enhanced phosphorylation of Src family kinase substrates containing SH2 domain binding sites. J Biol Chem (1998) 273(25):15325-15328.
106. Sondhi D, Xu W, Songyang Z, Eck MJ, Cole PA: Peptide and protein phosphorylation by protein tyrosine kinase CSK: Insights into specificity and mechanism. Biochemistry (1998) 37(1):165-172.
107. Lee S, Lin X, Nam NH, Parang K, Sun G: Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase. Proc Natl Acad Sci USA (2003) 100(25):14707-14712. The first study indicating the presence of a substrate-docking site for CSK.
108. Parang K, Cole PA: Designing bisubstrate inhibitors of protein kinases. Pharmacol Ther (2002) 93(2-3):145-157.
109. Parang K, Till JH, Ablooglu AJ, Kohanski RA, Hubbard SR, Cole PA: Mechanism-based design of a protein kinase inhibitor. Nat Struct Biol (2001) 8(1):37-41.
110. Hines AC, Cole PA: Design, synthesis and characterization of an ATP-peptide conjugate inhibitor of protein kinase A. Bioorg Med Chem Lett (2004) 14(11):2951-2954.
111. Singh J: Comparison of conservation within and between the Ser/Thr and Tyr protein kinase family: Proposed model for the catalytic domain of the epidermal growth factor receptor. Protein Eng (1994) 7(7):849-858.
112. Denny WA: Irreversible inhibitors of the ErbB family of protein tyrosine kinases. Pharmacol Ther (2002) 93(2-3):253-261.
113. Allen LF, Eiseman IA, Fry DW, Lenehan PF: CI-1033, an irreversible pan-ErbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol (2003) 30(5 Suppl 16):65-78.
114. Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, Rosfjord EC, Discafani C, Davis R, Shi X, Rabindran SK et al: Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3- carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem (2003) 46(1):49-63.
115. Vu CB: Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70. Curr Med Chem (2000) 7(10):1081-1100.
116. Vu CB, Corpuz EG, Pradeepan SG, Violette S, Bartlett C, Sawyer TK: Nonpeptidic SH2 inhibitors of the tyrosine kinase ZAP-70. Bioorg Med Chem Lett (1999) 9(20):3009-3014.
117. Müller G: Peptidomimetics SH2 domain antagonists for targeting signal transduction. In: Bioorganic Chemistry of Biological Signal Transduction. Waldmann H (Ed), Springer-Verlag, Berlin, Germany (2000) 211:17-59.
118. Vu CB, Corpuz EG, Merry TJ, Pradeepan SG, Bartlett C, Bohacek RS, Botfield MC, Eyermann CJ, Lynch BA, MacNeil IA, Ram MK et al: Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70. J Med Chem (1999) 42(20):4088-4098.
119. Cody WL, Lin Z, Panek RL, Rose DW, Rubin JR: Progress in the development of inhibitors of SH2 domains. Curr Pharm Des (2000) 6(1):59-98.
120. Sundaramoorthi R, Kawahata N, Yang MG, Shakespeare WC, Metcalf CA III, Wang Y, Merry T, Eyermann CJ, Bohacek RS, Narula S, Dalgarno DC et al: Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain:phosphotyrosine mimetics exploiting multifunctional group replacement chemistry. Biopolymers (2003) 71(6):717-729.
121. Waksman G, Kominos D, Robertson SC, Pant N, Baltimore D, Birge RB, Cowburn D, Hanfusa H, Majer BJ, Overduin M, Resh MD et al: Crystal structure of the phosphotyrosine recognition domain SH2 of v-Src completed with tyrosine-phosphorylated peptides. Nature (1992) 358(6388):646-653.
122. Waksman G, Shoelson SE, Pant N, Cowbum D, Kuriyan J: Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: Crystal structures of the complexed and peptide-free forms. Cell (1993) 72(5):779-790.
123. Lck. Nature (1993) 362(6415):87-91.
124. Kuriyan J, Cowbum D: Molecular peptide recognition domains in eukaryotic signaling. Annu Rev Biophys Biomol Struct (1997) 26:259-288.
125. Gilmer T, Rodriguez M, Jordan S, Crosby R, Alligood K, Green M, Kimery M, Wagner C, Kinder D, Charifson P et al: Peptide inhibitors of Src SH3-SH2-phosphoprotein interactions. J Biol Chem (1994) 269(50):31711-31719.
126. Lesuisse D, Lange G, Deprez P, Benard D, School B, Delettre G, Marquette JP, Broto P, Jean-Baptiste V, Bichet P, Sarubbi E et al: SAR and X-ray. A new approach combining fragment-based screening and rational drug design: Application to the discovery of nanomolar inhibitors of Src SH2. J Med Chem (2002) 45(12):2379-2387.
127. Park J, Fu H, Pei D: Peptidyl aldehydes as reversible covalent inhibitors of Src homology 2 domains. Biochemistry (2003) 42(17):5159-5167.
128. Nam NH, Ye G, Sun G, Parang K: Conformationally constrained peptide analogues of pTyr-Glu-Glu-IIe as inhibitors of the Src SH2 domain binding. J Med Chem (2004) 47(12):3131-3141.
129. Nam NH, Pitts R, Sun G, Sardari S, Tiemo A, Xie M, Yan B, Parang K: Design of tetrapeptide ligands as inhibitors of the Src SH2 domain. Bioorg Med Chem (2004) 12(4):779-787.
130. Shakespeare W, Yang M, Bohacek R, Cerasoli F, Stebbins K, Sundaramoorthi R, Azimioara M, Vu C, Pradeepan S, Metcalf C, Haraldson C et al: Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci USA (2000) 97(17):9373-9378.
131. 527-phosphorylated Src in an experimental in vivo system. Biochem Biophys Res Commun (2002) 298(2):185-192.
132. Liu X, Brodeur SR, Gish G, Songyang Z, Cantley LC, Laudano AP, Pawson T: Regulation of c-Src tyrosine kinase activity by the Src SH2 domain. Oncogene (1993) 8(5):1119-1126.
133. Alonso G, Koegl M, Mazurenko N, Courtneidge SA: Sequence requirements for binding of Src family tyrosine kinases to activated growth factor receptors. J Biol Chem (1995) 270(17):9840-9848.
134. 419 is phosphorylated. Biochemistry (1996) 35(29):9519-9525.
135. Pratt WB, Toft DO: Regulation of signaling protein function and trafficking by the Hsp90/Hsp70-based chaperone machinery. Exp Biol Med (2003) 228(2):111-133.
136. Sreedhar AS, Soti C, Csermely P: Inhibition of Hsp90: A new strategy for inhibiting protein kinases. Biochim Biophys Acta (2004) 1697(1-2):233-242. A comprehensive report on the status of Hsp90 inhibitors in protein kinase inhibitor design.
137. Neckers L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med (2002) 8(4 Suppl):S55-S61.
138. Boudeau J, Deak M, Lawlor MA, Morrice NA, Alessi DR: Heat shock protein 90 and Cdc37 interact with LKB1 and regulate its stability. Biochem J (2003) 370(Pt 3):849-857.
139. L and Bax downstream of 17-AAG-mediated downregulation of Akt, Raf-1 and Src kinases. Blood (2003) 102(1):269-275.